A post-hoc analysis was performed on the data from a @weeks phase III study ( ClinicalTrials.gov identifier : NCT@ ) to measure changes in the health-related quality of life ( HRQoL ) of @,@ patients aged @ with moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide ( OLM/AML/HCTZ ) , using the MINICHAL and EQ-@D instruments .